Brief Report: An Open Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC A12) as a First Line Therapy in Patients With …

Silvia Novello,Giorgio Vittorio Scagliotti,Gilberto de Castro,Murat Kiyik, Rubén Kowalyszyn, Karl Matthias Deppermann,Edurne Arriola,Lionel Bosquee,Ruslan D Novosiadly,Tuan S Nguyen,Amelie Forest,Shande Tang,Siva Rama Prasad Kambhampati,Jan Cosaert,Martin Reck

user-5ebe28934c775eda72abcddd（2017）

引用 0|浏览8

暂无评分

摘要

Type 1 insulin-like growth factor receptor (IGF-IR) is deregulated in solid tumors. Cixutumumab, a monoclonal antibody that inhibits IGF-IR activity, was investigated in combination with pemetrexed/cisplatin in the front-line setting.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要